Based in Delft, Bi/ond’s technology is already being deployed across The Netherlands and beyond, notably at Leiden University Medical Center, where clinicians are making heart tissues using Bi/ond’s microchips, and Erasmus University Medical Center, where researchers are developing breast cancer models that will eventually guide therapy selection. Bi/ond’s approach is to embrace human genetic variation in developing more inclusive and precision drugs for all populations . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

The post To Infinity and Bi/ond: Microchips Underpin Dutch Goal to Make Drug Development More Inclusive appeared first on GEN – Genetic Engineering and Biotechnology News.